APRIL is a secreted protein that will bind to TACI and B-cell maturation antigen (BCMA), a protein which has recently become a target for myeloma CAR-T cell therapy with an 88% response rate (98, 99). Here, TNFRSF17 is linked to plasma cell myeloma.